Solara Active Pharma Sciences reported consolidated revenue of ₹1,375.14 crores for FY2025-26, a 7% increase over ₹1,292.08 crores in FY2025, while posting a net loss of ₹7.41 crores against a marginal profit of ₹0.54 crores in the prior year.

The company has convened its Ninth Annual General Meeting on Friday, September 18, 2026, at 10.30 AM (IST) through Video Conferencing/Other Audio-Visual Means. The cut-off date for voting eligibility is September 11, 2026, with remote e-voting open from September 15 to September 17, 2026.

FY2025-26 Financial Performance

The following table summarises key consolidated financial metrics over five fiscal years:

Consolidated EBITDA declined 10% to ₹191.54 crores from ₹213.84 crores in FY25, with EBITDA margin contracting to 13.9% from 16.5%. The net loss was primarily impacted by continued weakness in the commodity Ibuprofen segment and a ₹5.89 crores exceptional item relating to past service cost from employee benefit plan amendments under the new Labour Codes.

Business Segment Performance

Base API Business

The base business — excluding commodity Ibuprofen — delivered revenue of ₹1,041.40 crores in FY2025-26, up 6% from ₹985 crores in FY25. Gross profit grew 6% to ₹573.20 crores, with gross margins at 55.0%. EBITDA remained stable at ₹244.50 crores, reflecting a 0.25% increase, with EBITDA margins of 23.5%. Regulated markets contributed nearly 75% of base business revenues.

Ibuprofen Business

The commodity Ibuprofen segment reported revenue of ₹333.74 crores, up 9% from ₹307 crores in FY25. However, gross profit declined 12% to ₹92.66 crores, and EBITDA deteriorated to ₹(52.96) crores — a 76% decline — reflecting persistent global oversupply and pricing pressure. The Board has initiated a strategic review of options for this business; the previously announced carve-out of the Polymers and CRAMS businesses has been deferred pending completion of this review, expected during H1 FY27.

Key Financial Ratios

Net debt reduced to ₹614 crores from ₹772 crores in FY25, supported by disciplined repayments, improved cash management, and Rights Issue proceeds. As of March 31, 2026, total funds received from the Rights Issue stood at ₹309.79 crores, including ₹155.31 crores from the First Call. Subsequent to the financial year close, the company received ₹1,29,94,28,775 towards the Second and Final Call on 1,15,50,478 partly paid-up Rights Equity Shares, converting them to fully paid-up shares on May 15, 2026.

Operational Highlights

• Six manufacturing facilities and one R&D centre, with approximately 1,700 employees
• 75% of revenues derived from regulated markets across 60+ countries
• Three successful USFDA audits across different sites in FY2025-26
• 50+ scientists advancing innovation and product development
• Renewable energy constituted approximately 50% of overall power consumption in FY26
• CSR investment of ₹0.76 crores in FY2025-26, focused on health, hygiene, and education

AGM Schedule

The Board did not recommend a final dividend for FY2025-26. Key AGM agenda items include adoption of audited financial statements, re-appointment of Mr. Arun Kumar Pillai as Non-Executive Director, ratification of Cost Auditor remuneration of ₹4.75 lakhs for FY27, and approval of material related party transactions with Strides Pharma Science Limited up to ₹480 crores.

Solara Active Pharma Sciences has revised the effective joining date of Mr. Ajit Manocha as Chief Information Officer (CIO) and Senior Management Personnel (SMP). The change pushes his start date from August 10, 2026, to August 17, 2026, following a request from Mr. Manocha on account of personal reasons. This update supersedes the company’s earlier intimation dated July 23, 2026, regarding his appointment.

The disclosure was made to the stock exchanges on August 07, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Pooja Jaya Kumar, Company Secretary & Compliance Officer, signed the communication.

Appointment Details

Mr. Manocha’s appointment remains confirmed for the role of CIO within the Senior Management Personnel framework. The delay does not alter the nature of the role or the strategic intent behind the hiring, but simply adjusts the timeline for his onboarding.

Profile Overview

Mr. Ajit Manocha brings over 33 years of experience in global technology and Life Sciences transformation. His expertise spans digital transformation across pharmaceuticals, CRDMOs, manufacturing, and other regulated industries. He specializes in aligning technology strategy with business goals, leading enterprise-wide SAP and S/4HANA transformations, and implementing Industry 4.0, IoT, cybersecurity, and AI/ML/Generative AI initiatives.

His background includes extensive work with Boards and senior leadership on technology strategy, cyber risk, and governance, ensuring the protection of intellectual property and data integrity in highly regulated environments. There are no disclosed relationships between Mr. Manocha and the company’s directors.